The popularity of GLP-1 weight-loss drugs has led to a surge in copycat medications as drug patents expire. Hims & Hers Health played a significant role in this trend by offering cheaper versions of these drugs, impacting the stocks of patent holders like Eli Lilly and Novo Nordisk.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay